<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04657705</url>
  </required_header>
  <id_info>
    <org_study_id>BURN VT</org_study_id>
    <nct_id>NCT04657705</nct_id>
  </id_info>
  <brief_title>Application of High Power Radio Frequency Energy in the Ventricular Tachycardia Treatment</brief_title>
  <official_title>Application of High Power Radio Frequency Energy in the Interventional Treatment of Patients With Ventricular Tachycardia and Structural Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Clinical Center of Federal Medical &amp; Biological Agency, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Meshalkin National Medical Research Center, Ministry of Health of Russian Federation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heart and Vascular Center Bad Bevensen, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Medical Research Center for Cardiology, Ministry of Health of Russian Federation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Research Center of Surgery, Russia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>I.M. Sechenov First Moscow State Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Cardiac Arrhythmia Institute, Austin, Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal Research Clinical Center of Federal Medical &amp; Biological Agency, Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Patient's freedom from VT after RFA remains non-optimal and it depends on many&#xD;
      factors. One of them is the effective reduction of the myocardium with RF energy during the&#xD;
      operation. The standardization of the parameters of RF will help to increase the success of&#xD;
      the procedure.&#xD;
&#xD;
      Hypothesis: Radiofrequency ablation of ventricular tachycardias with high power parameters&#xD;
      has comparable safety and leads to greater efficacy (absence of ventricular tachycardias and&#xD;
      all types of cardioverter-defibrillator therapies) in the long-term compared with ablation&#xD;
      with standard parameters in patients with structural heart disease.&#xD;
&#xD;
      Purpose: to evaluate the safety and the efficiency of ablation of ventricular tachycardia in&#xD;
      patients with structural heart disease using high power RF energy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Patient's freedom from VT after RFA remains non-optimal and it depends on many&#xD;
      factors. One of them is the effective reduction of the myocardium with RF energy during the&#xD;
      operation. The standardization of the parameters of RF will help to increase the success of&#xD;
      the procedure.&#xD;
&#xD;
      Hypothesis: Radiofrequency ablation of ventricular tachycardias with high power parameters&#xD;
      has comparable safety and leads to greater efficacy (absence of ventricular tachycardias and&#xD;
      all types of cardioverter-defibrillator therapies) in the long-term compared with ablation&#xD;
      with standard parameters in patients with structural heart disease.&#xD;
&#xD;
      Purpose: to evaluate the safety and the efficiency of ablation of ventricular tachycardia in&#xD;
      patients with structural heart disease using high power RF energy.&#xD;
&#xD;
      Tasks:&#xD;
&#xD;
        1. To analyze the number of intraoperative complications in both groups&#xD;
&#xD;
        2. To evaluate the number of recurrent ventricular tachycardias and the number of episodes&#xD;
           of CDI therapy in the long-term follow-up period&#xD;
&#xD;
        3. To estimate the time of onset of the first episode of VT and the overall burden of VT in&#xD;
           the long-term follow-up period&#xD;
&#xD;
        4. To compare the total time of surgery, fluoroscopy, the number and total time of RF&#xD;
           exposure, as well as the ablation index in relation to the &quot;acute&quot; and separated&#xD;
           efficiency of ablation in the study groups&#xD;
&#xD;
        5. To estimate all-cause mortality in both groups&#xD;
&#xD;
        6. The number of repeated ablation for recurrent VT&#xD;
&#xD;
        7. The number of justified and unfounded CDI therapies&#xD;
&#xD;
        8. To analyze the long-term burden of antiarrhythmic therapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2020</start_date>
  <completion_date type="Anticipated">September 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of intraoperative complications</measure>
    <time_frame>Day 1</time_frame>
    <description>The number of intraoperative complications (death, hemopericardium, stroke, heart attack, electrical storm, vascular complications)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The inducibility of the clinical VT at the end of ablation procedure</measure>
    <time_frame>Day 1</time_frame>
    <description>The number of patients with inducible VT at the end of the ablation procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of recurrent ventricular tachycardias</measure>
    <time_frame>Up to one year</time_frame>
    <description>The number of recurrent ventricular tachycardias on one-year follow-up period after single procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of episodes of ICD therapy</measure>
    <time_frame>Up to one year</time_frame>
    <description>The number of episodes of ICD therapy on one-year follow-up period after single procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from recurrent VT</measure>
    <time_frame>3 months</time_frame>
    <description>Time to the first episode of VT on 3 months follow-up period after single procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total time of ablation procedure</measure>
    <time_frame>Up to one year</time_frame>
    <description>The total time of ablation procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total time of fluoroscopy</measure>
    <time_frame>Up to one year</time_frame>
    <description>The total time of fluoroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total number of RF exposures</measure>
    <time_frame>Up to one year</time_frame>
    <description>The total number of RF exposures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total time of RF exposures</measure>
    <time_frame>Up to one year</time_frame>
    <description>The total time of RF exposures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Up to one year</time_frame>
    <description>All-cause mortality (Time to any death occurring at any time on one-year follow-up period )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of redo ablation procedures for recurrent VT</measure>
    <time_frame>Up to one year</time_frame>
    <description>The number of redo ablation procedures for recurrent VT on one-year follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of appropriate and unappropriated ICD therapies</measure>
    <time_frame>Up to one year</time_frame>
    <description>The number of appropriate and unappropriated ICD therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of antiarrhythmic drugs</measure>
    <time_frame>Up to one year</time_frame>
    <description>The number of antiarrhythmic drugs on one-year follow-up period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <condition>Heart Diseases</condition>
  <arm_group>
    <arm_group_label>High power ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High power ablation parameters (50-55 W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard ablation power</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard ablation power parameters (40-45 W)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>High power ablation</intervention_name>
    <description>High power ablation parameters (50-55 W)</description>
    <arm_group_label>High power ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard ablation power</intervention_name>
    <description>Standard ablation power parameters (40-45 W)</description>
    <arm_group_label>Standard ablation power</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients after myocardial infarction (at least 3 months before enrollment in the&#xD;
             study)&#xD;
&#xD;
          2. Stable, documented, monomorphic VT, confirmed by ECG and / or CMECG and / or EGM of&#xD;
             any implanted device, having appropriate rhythm discrimination algorithms&#xD;
&#xD;
          3. Patients who have signed the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute myocardial ischemia&#xD;
&#xD;
          2. A reversible cause of VT (e.g. drug arrhythmia), recently(up to 30 days) suffered from&#xD;
             acute coronary syndrome, coronary revascularization (&lt;90 days for bypass surgery, &lt;30&#xD;
             days for percutaneous coronary intervention), or having functional class IV angina.&#xD;
&#xD;
          3. Thrombosis of the left ventricle&#xD;
&#xD;
          4. Patients who have been implanted the mechanical prostheses in the aortic and mitral&#xD;
             positions.&#xD;
&#xD;
          5. Patients who have been performed the catheter RFA for VT.&#xD;
&#xD;
          6. Renal failure (creatinine clearance &lt;15 ml / min),&#xD;
&#xD;
          7. Patients with NYHA functional class IV heart failure&#xD;
&#xD;
          8. Patients with a medical condition that may limit survival to less than 1 year&#xD;
&#xD;
          9. Patients with myocardial infarction with ST-segment elevation or MI without ST-segment&#xD;
             elevation, transferred less than 30 days ago.&#xD;
&#xD;
         10. Patients who haven't signed the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey V. Korolev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal Research Clinical Center FMBA Russia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sergey V. Korolev, MD</last_name>
    <phone>+7 916 348-76-55</phone>
    <email>sergejkorolev@yandex.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Institute</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78749</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Natale</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heart and Vascular Center</name>
      <address>
        <city>Bad Bevensen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeny Lyan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federal Research Clinical Center of Federal Medical &amp; Biological Agency</name>
      <address>
        <city>Moscow</city>
        <zip>115682</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergey V. Korolev, MD</last_name>
      <phone>+7 916 348-76-55</phone>
      <email>sergejkorolev@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Medical Research Center of Surgery named after A. Vishnevsky</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amiran Revishvili</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>I.M. Sechenov First Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexey Tsyganov</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Medical Research Center of Cardiology</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleg Sapilnikov</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meshalkin National Medical Research Center</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander B. Romanov</last_name>
      <phone>+7 913 717-26-52</phone>
      <email>abromanov@mail.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High Power Radio Frequency Energy</keyword>
  <keyword>Ventricular Tachycardia</keyword>
  <keyword>Structural Heart Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no current plan to share individual participant data (IPD).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

